Japanese study finds CathWorks FFRangio offers similar clinical outcomes to traditional methods with cost savings and fewer resources.

The PROVISION Study, a randomized controlled trial in Japan, evaluated the CathWorks FFRangio® System, a non-invasive technology for diagnosing coronary artery disease. It found that FFRangio offers similar clinical outcomes to traditional wire-based methods while reducing costs by about $374 to $400 per patient and requiring fewer resources. The study highlights FFRangio's efficiency, lower radiation exposure, and enhanced patient comfort, marking a significant advancement in cardiovascular diagnostics.

October 27, 2024
3 Articles

Further Reading